^
Association details:
| Biomarker: | HGF elevation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma
Published date:
01/03/2023
Excerpt:
...we report a biomarker analysis and update the efficacy and safety results of cabozantinib treatment….Nonresponders to cabozantinib showed relatively higher HGF levels than responders at baseline.
DOI:
10.1007/s10147-022-02283-w
